Thrombosis in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is linked to an increased risk of venous thromboembolic events (VTE).
• Chemotherapy, steroids, and antiangiogenic agents used in MM treatment can further elevate VTE risk.
• Understanding the prothrombotic mechanisms in MM is crucial for targeted antithrombotic prophylaxis.

Purpose of the Study:

• To identify measurable factors contributing to the prothrombotic state in multiple myeloma.
• To evaluate the efficacy of thromboprophylaxis strategies in MM patients.
• To explore potential survival benefits beyond anticoagulation for specific antithrombotic agents.

Main Methods:

• Review of mechanisms contributing to thrombosis in MM, including inflammatory cytokines, factor VIII, von Willebrand factor, protein C system, and plasma immunoglobulin effects on fibrinolysis.
• Analysis of thromboprophylaxis strategies using low molecular weight heparin, warfarin, or aspirin in patients receiving MM therapies (e.g., thalidomide/chemotherapy, lenalidomide/dexamethasone).

Main Results:

• Malignancy-associated thrombophilia, paraprotein-specific factors, and treatment-induced changes contribute to high thrombosis rates in MM.
• Inflammatory cytokines elevate procoagulant factors and downregulate anticoagulant pathways.
• Elevated plasma immunoglobulin levels can impair fibrinolysis.
• Thromboprophylaxis with low molecular weight heparin, warfarin, or aspirin has demonstrated efficacy in MM patients.

Conclusions:

• Antithrombotic prophylaxis is effective in reducing VTE risk in multiple myeloma patients undergoing treatment.
• Low molecular weight heparin and aspirin may offer survival benefits in MM patients, extending beyond their anticoagulant properties.
• Further research into the multifaceted prothrombotic mechanisms and survival impacts of anticoagulation in MM is warranted.